Inflabion

Diacerein, the active ingredient in Inflabion, is a disease-modifying osteoarthritis drug presented as a tablet for oral use. It is indicated for the management of osteoarthritis of the knee and hip, providing symptomatic relief and slowing cartilage degradation in adult patients.

GNH USA supplies Inflabion as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inflabion (diacerein) acts on inflammatory pathways involved in osteoarthritis, helping to modify disease progression.

- Osteoarthritis of the knee: reduces pain and slows cartilage loss in the knee joint. - Osteoarthritis of the hip: alleviates discomfort and decelerates joint degeneration in the hip. - Osteoarthritis of other joints: may provide symptomatic benefit and improve joint function.

Diacerein may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Diarrhea - Abdominal pain - Nausea - Dyspepsia - Flatulence - Constipation

Serious or Rare Side Effects: - Elevated liver enzymes or hepatitis - Severe allergic reactions such as Stevens‑Johnson syndrome - Blood dyscrasias (e.g., neutropenia, agranulocytosis) - Severe skin reactions - Hepatic failure

When prescribing diacerein, clinicians should consider several safety measures.

- Liver function monitoring: assess hepatic enzymes before and during therapy. - Gastrointestinal tolerance: take with food to reduce irritation. - Elderly patients: consider lower starting dose and close observation. - Renal impairment: evaluate kidney function prior to initiation. - Concomitant NSAID use: increased risk of gastrointestinal adverse events; consider alternatives. - Store at ambient temperature: keep below 25°C, protect from moisture in the original packaging.

Diacerein can interact with several medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect may raise bleeding risk. - Strong CYP2C9 inhibitors (e.g., fluconazole): may raise diacerein plasma levels. - Concurrent NSAIDs: additive gastrointestinal toxicity.

Moderate Interactions (Monitor Closely): - Antacids (e.g., aluminum hydroxide): may reduce diacerein absorption. - Corticosteroids: combined use may heighten GI ulcer risk. - Diuretics: monitor electrolytes as diacerein may affect fluid balance.